These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 17216246)

  • 21. [Microalbuminuria in patients with hypertension and cardiovascular comorbidity, REAL observational study of treatment with Irbesartan/HCTZ].
    Tschöpe C; Tschöpe R; Unger T
    MMW Fortschr Med; 2006 Jun; 148(25):48. PubMed ID: 16859162
    [No Abstract]   [Full Text] [Related]  

  • 22. Irbesartan in patients with atrial fibrillation.
    ; Yusuf S; Healey JS; Pogue J; Chrolavicius S; Flather M; Hart RG; Hohnloser SH; Joyner CD; Pfeffer MA; Connolly SJ
    N Engl J Med; 2011 Mar; 364(10):928-38. PubMed ID: 21388310
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oligohydramnios and pulmonary hypoplasia: a case in which involvement of an angiotensin II receptor antagonist was suspected.
    Kato K; Okuda M; Ishikawa H; Takahashi T; Hirahara F
    J Obstet Gynaecol Res; 2008 Apr; 34(2):242-6. PubMed ID: 18412789
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Irbesartan in clinical practice].
    Malishevskiĭ MV
    Kardiologiia; 2012; 52(11):66-74. PubMed ID: 23237398
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Anticoagulation in atrial fibrillation. ACTIVE Study (Arterial fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events)].
    Meinertz T
    Internist (Berl); 2007 Aug; 48(8):874-5. PubMed ID: 17628764
    [No Abstract]   [Full Text] [Related]  

  • 26. Angiotensin II receptor blockers in pregnancy: a case report and systematic review of the literature.
    Velázquez-Armenta EY; Han JY; Choi JS; Yang KM; Nava-Ocampo AA
    Hypertens Pregnancy; 2007; 26(1):51-66. PubMed ID: 17454218
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [IRMA-pRAcs: irbesartan in the treatment of microalbuminuria and proteinuria in patients with type 2 diabetes and hypertension-prospective observational study involving 38,016 patients in the general practice setting].
    Lehnert H; Bramlage P; Pittrow D; Kirch W
    MMW Fortschr Med; 2003 Oct; 145 Suppl 3():81-7. PubMed ID: 15490772
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Observational study of blood pressure control and microalbuminuria in type 2 diabetics on irbesartan or irbesartan/HCTZ].
    Schmieder RE; Krekler M
    MMW Fortschr Med; 2005 Oct; 147 Suppl 3():97-101. PubMed ID: 16261944
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study.
    Palatini P; Jung W; Shlyakhto E; Botha J; Bush C; Keefe DL
    J Hum Hypertens; 2010 Feb; 24(2):93-103. PubMed ID: 19458624
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized placebo controlled trial of early treatment of acute ischemic stroke with atorvastatin and irbesartan.
    Beer C; Blacker D; Bynevelt M; Hankey GJ; Puddey IB
    Int J Stroke; 2012 Feb; 7(2):104-11. PubMed ID: 22044557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevention of recurrences in patients with lone atrial fibrillation. The dose-dependent effect of angiotensin II receptor blockers.
    Madrid AH; Marín IM; Cervantes CE; Morell EB; Estévez JE; Moreno G; Parajón JR; Peng J; Limón L; Nannini S; Moro C
    J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5(3):114-20. PubMed ID: 15526246
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Angiotensin II receptor blockers in pregnancy: a report of five cases.
    Gersak K; Cvijic M; Cerar LK
    Reprod Toxicol; 2009 Jul; 28(1):109-12. PubMed ID: 19491003
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of anemia with erythropoietin-stimulating agents in kidney transplant recipients and chronic kidney disease-another drawback of immunosuppression?
    Malyszko J; Glowinska I; Mysliwiec M
    Transplant Proc; 2012 Dec; 44(10):3013-6. PubMed ID: 23195016
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
    Lewis EJ; Hunsicker LG; Clarke WR; Berl T; Pohl MA; Lewis JB; Ritz E; Atkins RC; Rohde R; Raz I;
    N Engl J Med; 2001 Sep; 345(12):851-60. PubMed ID: 11565517
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET.
    Philipp T; Martinez F; Geiger H; Moulin B; Mourad G; Schmieder R; Lièvre M; Heemann U; Legendre C
    Nephrol Dial Transplant; 2010 Mar; 25(3):967-76. PubMed ID: 19887503
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fimasartan, a novel angiotensin II receptor antagonist.
    Kim JH; Lee JH; Paik SH; Kim JH; Chi YH
    Arch Pharm Res; 2012 Jul; 35(7):1123-6. PubMed ID: 22864732
    [TBL] [Abstract][Full Text] [Related]  

  • 37. I-COMBINE study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with amlodipine monotherapy in hypertensive patients uncontrolled with amlodipine 5 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study.
    Bobrie G;
    Clin Ther; 2012 Aug; 34(8):1705-19. PubMed ID: 22853848
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and tolerability of fixed-dose irbesartan/hydrochlorothiazide for rapid control of severe hypertension.
    Neutel JM; Franklin SS; Bhaumik A; Lapuerta P; Oparil S
    Clin Exp Hypertens; 2009 Oct; 31(7):572-84. PubMed ID: 19886855
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identifying patterns of adverse event reporting for four members of the angiotensin II receptor blockers class of drugs: revisiting the Weber effect.
    McAdams MA; Governale LA; Swartz L; Hammad TA; Dal Pan GJ
    Pharmacoepidemiol Drug Saf; 2008 Sep; 17(9):882-9. PubMed ID: 18636418
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Determinants of persistence in hypertensive patients treated with irbesartan: results of a postmarketing survey.
    Burnier M; Hess B; Greminger P; Waeber B
    BMC Cardiovasc Disord; 2005 Jun; 5(1):13. PubMed ID: 15943871
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.